First, awareness of NUEDEXTA amongst physicians continues to grow and reached an all-time high in our recently completed market research. This demonstrates that our sales and marketing initiatives are continuing to have significant impact in the marketplace.Second, the number of physicians prescribing NUEDEXTA each week continues to grow here again reaching an all time high in June. Similarly our reach amongst nursing homes is also increasing and we now cover over a third of the beds in the country.
Avanir Pharmaceuticals' CEO Discusses F3Q12 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.